HENDERSON, Nev. , Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024 .
Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development strategies within both large and small companies.
Tim has been directly responsible for building the commercial viability at his previous companies, many through to acquisition. His most recent operating role was President and CEO of Sense Biodetection. Early in 2023, Sense Bio merged with Sherlock Biosciences to create a leading point of care diagnostics company serving the consumer diagnostics market.
Prior to Sense Biodetection, Mr. Still has been a CEO and/or a board member at numerous medical technology companies: Myoscience, MDx Health, Gold Standard Diagnostics (Executive Chairman), Global Kinetics, Xagenic and Accumetrics. Earlier in his career, Tim also held senior leadership roles at HemoSense, Cholestech, and Boehringer Mannheim/Roche.
Mr. Still has a master's degree in business administration (Dean's Scholar) from the University of Southern California , and a Bachelor of Science d.